Royalty Pharma and J&J partner to develop autoimmune treatment [Yahoo! Finance]
Royalty Pharma plc - Class A Ordinary Shares (RPRX)
US:NASDAQ Investor Relations:
ir.reprosrx.com/investor-relations
Company Research
Source: Yahoo! Finance
Shares of Royalty Pharma were up 1.4% in premarket ?trading, while ?those of J&J rose nearly 0.7%. * The co-funding agreement, covering ?2026 and 2027, willsupport the development of JNJ-4804, an experimental ?co-antibodytherapy that ?targets IL ?23 and TNF, ?two immune pathways involvedin autoimmune inflammation. * Royalty Pharma CEO Pablo Legorreta said the drug holdspromise for patients with chronic immune-mediated diseases ?andthat the agreement ?builds on the ?company's investments ?inimmunology, including earlier medicines ?targeting TNF. * The biopharmaceutical investor ?receives ?royalties onmore than 35 commercial products, including Biogen's Tysabri andJ&J's ?Tremfya - ?both targeting autoimmune disorders. (Reporting by Kunal ?Das in Bengaluru; Editing ?by Diti Pujara)
Show less
Read more
Impact Snapshot
Event Time:
RPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPRX alerts
High impacting Royalty Pharma plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
RPRX
News
- 1 Cash-Producing Stock to Own for Decades and 2 That Underwhelm [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated DiseasesGlobeNewswire
- Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma Appoints Lucas Glass as Head of Artificial IntelligenceGlobeNewswire
- How The Royalty Pharma (RPRX) Story Is Shifting With New Deals And Updated Expectations [Yahoo! Finance]Yahoo! Finance
RPRX
Sec Filings
- 3/31/26 - Form 4
- 3/23/26 - Form 144
- 3/19/26 - Form 144
- RPRX's page on the SEC website